● Shorter Path to XRx-008 Marketing Approval ●

CALGARY, Alberta, Oct. 23, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease (“PKD”), is pleased to announce that the Company’s clinical development plan has been reviewed and accelerated. 

CALGARY, Alberta, Oct. 15, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the addition of two new members to the Company’s clinical advisory board, Dr.

• Phase II Clinical Study in ADPKD Planned

CALGARY, Alberta, Sept. 10, 2018 (GLOBE NEWSWIRE) —  XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company along with its collaborative partner, Cato Clinical Research, has submitted documents to the US Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) status for XORTX’s XRx-008 (a proprietary formulation of Oxypurinol) program for the treatment of autosomal dominant polycystic kidney disease ( ADPKD).

● Advancing to a Phase II Clinical Study in Polycystic Kidney Disease ●

CALGARY, Alberta, Aug. 13, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX; OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company with its collaborative partner, Cato Clinical Research, has filed its pre-IND meeting documents with the FDA.  

CALGARY, Alberta, June 08, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the Company along with Cato Clinical Research has filed its pre-IND meeting request letter with the FDA.  

CALGARY, Alberta, June 06, 2018 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that the Company’s shares have been approved to commence trading on the OTCQB Venture Market under the symbol XRTXF effective June 7, 2018.